Cargando…
BI-847325, a selective dual MEK and Aurora kinases inhibitor, reduces aggressive behavior of anaplastic thyroid carcinoma on an in vitro three-dimensional culture
BACKGROUND: Anaplastic thyroid carcinoma (ATC) is the most aggressive subtype of thyroid cancer. In this study, we used a three-dimensional in vitro system to evaluate the effect of a dual MEK/Aurora kinase inhibitor, BI-847325 anticancer drug, on several cellular and molecular processes involved in...
Autores principales: | Samimi, Hilda, Tavakoli, Rezvan, Fallah, Parviz, Naderi Sohi, Alireza, Amini Shirkouhi, Maryam, Naderi, Mahmood, Haghpanah, Vahid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730667/ https://www.ncbi.nlm.nih.gov/pubmed/36482411 http://dx.doi.org/10.1186/s12935-022-02813-6 |
Ejemplares similares
-
Alginate-based 3D cell culture technique to evaluate the half-maximal inhibitory concentration: an in vitro model of anticancer drug study for anaplastic thyroid carcinoma
por: Samimi, Hilda, et al.
Publicado: (2021) -
High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
por: Vuaroqueaux, Vincent, et al.
Publicado: (2023) -
GANT61/BI-847325 combination: a new hope in lung cancer treatment
por: El-Kishky, Abdel Halim M., et al.
Publicado: (2022) -
Development of a Multiepitope Vaccine Against SARS-CoV-2: Immunoinformatics Study
por: Ghafouri, Fatemeh, et al.
Publicado: (2022) -
Molecular mechanisms of long non-coding RNAs in anaplastic thyroid cancer: a systematic review
por: Samimi, Hilda, et al.
Publicado: (2020)